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Background: Intrapartum complications are responsible for approximately half of all maternal deaths, and two million
stillbirth and neonatal deaths per year. Prolonged second stage of labour is associated with potentially fatal maternal
complications such as haemorrhage and infection and it is a major cause of stillbirth and newborn morbidity and
mortality. Currently, the three main options for managing prolonged second stage of labour are forceps, vacuum
extractor and caesarean section. All three clinical practices require relatively expensive equipment (e.g., a surgical
theatre for caesarean section) and/or highly trained staff which are often not available in low resource settings. The
specific aim of the proposed study is to test the safety and feasibility of a new device (Odón device) to effectively
deliver the fetus during prolonged second stage of labour. The Odón device is a low-cost technological innovation to
facilitate operative vaginal delivery and designed to minimize trauma to the mother and baby. These features
combined make it a potentially revolutionary development in obstetrics, particularly for improving intrapartum care
and reducing maternal and perinatal morbidity and mortality in low resource settings.
Methods/design: This will be a hospital-based, multicenter prospective phase 1 cohort study with no control group.
Delivery with the Odón device will be attempted under normal labour and non-emergency conditions on all the
women enrolled in the study. One-hundred and thirty pregnant women will be recruited in tertiary care facilities in
Argentina. Safety will be assessed by examining maternal and infant outcomes until discharge. Feasibility will be
evaluated by observing successful expulsion of the fetal head after one-time application of the device under
standardized conditions (full cervical dilation, anterior presentation, +2 station, normal fetal heart rate).
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR). Identifier: ACTRN12613000141741
Keywords: Assisted vaginal delivery, Obstructed labour, Intrapartum complications, Odón device, Maternal mortality,
Maternal morbidity, Fetal mortalityBackground
Intrapartum complications are responsible for approxi-
mately half of all maternal deaths, and two million stillbirth
and neonatal deaths per year [1-5]. Prolonged second stage
of labour is associated with potentially fatal maternal com-
plications such as haemorrhage and infection and it is a
major cause of stillbirth and newborn morbidity and mor-
tality. It also increases the risk of vaginal and perineal* Correspondence: betrana@who.int
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which permits unrestricted use, distribution, atears and instrumental deliveries. The three main options
for managing prolonged second stage of labour are for-
ceps, vacuum extractor, and caesarean section. The use of
forceps and vacuum extractor during prolonged second
stage of labour is associated with increased perinatal mor-
bidity [6-15]. Cephalohematoma and retinal haemorrhages
have been associated with the use of vacuum extractor
while external ocular injury and facial nerve palsy have
been associated with forceps deliveries [15]. Evidence indi-
cates that vacuum extraction is significantly less likely to
achieve successful vaginal delivery than forceps but it is
associated with lower caesarean deliveries, probably becauseDevice Research Group; licensee BioMed Central Ltd. This is an Open Access
tive Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
nd reproduction in any medium, provided the original work is properly cited.
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Vacuum extraction is also contra-indicated in women who
are HIV positive or with unknown status. On the other
hand, use of vacuum extractor results in lower rates of
perineal trauma, tears, requirements for pain relief and
incontinence in comparison with forceps [15].
Caesarean delivery in the second stage of labour ac-
counts for approximately one fourth of all primary cae-
sarean sections [16]. Although second stage caesarean
sections are sometimes appropriate for medically indi-
cated reasons, many of them could be avoided by obstetri-
cians skilled in performing operative vaginal deliveries [17].
However, fewer health care professionals are receiving
appropriate training in operative vaginal deliveries. This
change in medical curriculum is contributing to the ob-
served declining trend in the use of operative vaginal
deliveries and presents a challenge for maintaining and
developing these skills [18].
Rationale for the trial: opportunity for development
of alternatives
All three available clinical practices for managing prolonged
second stage of labour require relatively expensive equip-
ment (e.g., a surgical theatre for caesarean section) and/or
highly trained staff that are often not available in low re-
source settings.
Evidence indicates that the majority of intrapartum
deaths in low-resource settings could be prevented through
the introduction of innovative strategies that would in-
crease accessibility of obstetric care (e.g., task shifting) [4].
Technological developments such as the Odón device that
reduces the skill level and equipment required to provide
quality obstetric care are clearly needed.
The Odón device (see Figure 1; http://www.odondevice.
com/) is envisioned to be a possible alternative to availableFigure 1 The Odón device: a new, simple instrument for
assisted vaginal deliveries.management options for complicated second stage of
labour. It may be potentially safer and easier to apply than
forceps/vacuum extractor for assisted deliveries, and a safe
alternative to some caesarean sections. It has potential for
wide application in low-resource settings, even by mid-
level providers. If proven safe and effective, the Odón
device will be the first innovation in operative vaginal
delivery since the independent development of forceps
and the vacuum extractor centuries ago. The Odon device
could play a major role in improving intrapartum ob-
stetric care in low resource settings by making possible
effective management of intrapartum complications in
facilities lacking surgical capacity and/or personnel ad-
equately trained in the use of forceps and the vacuum ex-
tractor. Future research may explore additional uses of
the device to prevent vertical transmission of infections
during childbirth.
Description of the device and preliminary result in simulators
In comparison with available instruments for operative va-
ginal delivery (forceps and vacuum extractor), the Odón
device presents specific features that could potentially
reduce the risk of maternal and fetal injury. The Odón de-
vice is made of inexpensive film-like polyethylene material
(Figure 1) and it is designed to be easily applied with the
help of an inserter requiring minimal training. The appli-
cation and use of the Odón device is shown in Figure 2.
Studies in animals have been ruled out for several rea-
sons. In most animals, the head is not the presenting part
in normal delivery. Theoretically, experimentation of the
Odón device would have been possible in superior pri-
mates (chimpanzee, gorilla, and orangutan). However, in
practice this option is not feasible because any experimen-
tal procedure concerning childbirth with these primates
would require general anaesthesia, which would interfere
with the physiological mechanisms of labour.
The Odón device was tested under conditions simulating
normal delivery at the Simulation Centre of Des Moines
University, USA in December 2008. The simulator S 575
(Noelle) which closely simulates a mother-fetus dyad in
labour and delivery was used. Under those experimental
conditions, the application of the Odón device consist-
ently allowed for the immediate expulsion of the fetus in
multiple trials. At that time, the device had never been
tested in humans or animal models.
Study hypothesis and objectives
The main objective of this study is to evaluate the safety
and feasibility, in terms of ease of application and suc-
cessful use of the Odón device in assisting vaginal delivery
in singleton term pregnancies during the second stage of
labour. The hypothesis is that the Odón device is safe, easy
to use, allows for successful delivery, and is accepted by
both women and obstetricians.
1
The inserter is applied on the head of the baby. A soft plastic 
bell assures perfect adaptation to the fetal head and prevents 
damage.
2
The inserter progressively positions the Odón device around 
the head of the baby. Positioning occurs as the inserter gently 
produces the sliding of the two surfaces of the folded sleeve 
along the birth canal and around the baby’s head.
3
When the Odón device is properly positioned, a marker on the 
insertion handle become clearly visible in the reading window. 
A minimal and self-limited amount of air is pumped into an air 
chamber in the inner surface.
4
This produces a secure grasp around the head of the baby that 
removed.
5
the two surfaces of the folded sleeve. Lubrication of the 
surfaces further facilitates the extraction process. If needed, 
traction can be applied up to 19 kg (which is equivalent to the 
force applied with the metal vacuum extractor).
Figure 2 Visualization of the use of the Odón device.
The World Health Organization Odon Device Research Group Reproductive Health 2013, 10:33 Page 3 of 8
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fant outcomes. Feasibility will be evaluated by observing
successful expulsion of the fetal head after one-time ap-
plication of the device under standardized conditions
(full cervical dilation, anterior presentation, +2 station,
normal fetal heart rate) in singleton non-complicated
pregnancies. Successful expulsion would be defined as
the complete expulsion of the head of the baby with the
device. Cases of crowning will be recorded. Successful
application of the device will be defined as (1) reaching
number 4 or 5 in the reading window of the inserter, (2)successful inflation of the device without leaks after the
expulsion, and (3) successful expulsion.Study conceptual framework
This proposed protocol is embedded in a larger two-
phased study:
PHASE 1: the device will be tested for safety and feasi-
bility in terms of ease of application and successful deliv-
ery under non-emergency/normal delivery conditions. 130
women will be recruited for delivery using the Odón
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protocol refers to Phase 1 of this study.
PHASE 2: the device will be tested for preliminary effi-
cacy (successful delivery of the baby without the need to
resort to caesarean section/forceps/vacuum extractor) in
deliveries with prolonged second stage of labour with an
indication for not immediate operative delivery (allowing
enough time for the application of the Odón device prior
to standard of care) and no signs of fetal distress. 128
women will be randomly allocated either to: (1) standard
of care (forceps/vacuum extractor); or (2) application of
the Odón device. Preliminary efficacy will be assessed
by determining the number of successful deliveries by
Odón device.
Methods/design
This will be a hospital-based, multicentre prospective
cohort with no control group. Delivery with the Odón
device will be attempted under non-emergency/normal
delivery conditions on all women enrolled in the study.
Outcome measures
The different measures collected will be used to assess
safety and feasibility. Safety will be assessed by examining
maternal and infant outcomes at labour, delivery and im-
mediate postpartum care until discharge. Feasibility will
be evaluated by observing successful expulsion of the fetal
head after one-time application of the device under stan-
dardized conditions as explained above. The list of out-
come indicators for Phase 1 are presented in Table 1.
Study population
Pregnant women must meet all of the following inclu-
sion criteria to be eligible for enrolment in the study and
application of the Odón device during delivery:
1. Written informed consent obtained during an
antenatal care visit, and always before the initiation
of labour;
2. Age greater than or equal to 18 years and less than
or equal to 35 years;
3. Singleton pregnancy;
4. Gestational age equal to or more than 37 weeks by
best estimate according to local protocols;
5. Live fetus by the methods used with local protocols;
6. Fully dilated cervix;
7. Ruptured membranes (spontaneous or artificial);
8. Any anterior occiput presentation;
9. Station level equivalent to 2 cm or more below the
spines (e.g. station +2 or lower);
10. Fetal heart rate pattern recorded by continuous fetal
electronic monitoring meeting the following criteria:a. Stable baseline rate between 110 and 160 beats/minb. normal short and long term variability
c. absence of late decelerations.Exclusion criteria
Women presenting any of the following conditions will not
be included in the study and the device will not be applied:
1. Suspected or confirmed maternal infection:
suspected infection will be diagnosed if any of the
following are present:
a) Fever greater than or equal to 38°C
b) Foul smelling amniotic fluid
2. Prolonged rupture of membranes (more than
24 hours)
3. Meconium stained
4. History of coagulation disorder
5. Previous uterine surgery
6. Intrapartum haemorrhage
7. Suspected cephalopelvic disproportion or need of
operative delivery
8. Known recto-vaginal Streptoccocus B Haemolyticcus
positive culture
9. Known HIV positive status
10.Any condition or circumstance that, in investigator’s
opinion, would compromise the safety of the mother
or the fetus.
Sample size calculation
One-hundred and thirty pregnant women will be enrolled
in phase 1 at participating centers. The sample size was
determined in consideration of the study objective of
assessing maternal and fetal safety. This sample size is
considered feasible in the proposed research settings
and will allow for detecting frequencies of maternal
and/or fetal complications between 2% and 20% with a
95% confidence interval width not larger than 15%, as
shown in Table 2.
Participant recruitment plan
At all study sites, women will be approached during
antenatal visits by a midwife who will explain the study
objective and procedures. If the woman agrees to receive
more information about the study, she will be fully briefed
by a member of the study team who will review the con-
sent form and show her the Odón device and how it
functions. An explanatory video will also be made avail-
able. The woman will not be asked to sign the consent
form immediately. Instead she will be given the infor-
mation sheet to take home to think about it and discuss
with family members if she wishes. She can sign the con-
sent form when she returns for the next antenatal visit.
Consent will be obtained before the initiation of labour
and women will be able to withdraw from the study at
any time.
Table 1 Study outcomes
Labour and delivery
At the time of device application • Time from application of device to delivery of the cephalic pole
• Failure rate of device application (only one attempt will be made)
• Incidence of:
○ Operative delivery with forceps or vacuum
○ Caesarean section
We anticipate that there may be some cases in which the device will present
the following: it cannot be applied, it is difficult to apply, it slips off, or it is ineffective.
To determine the clinical circumstances under which such problems occur,
the following clinical data will be collected:
• Position of head
• Station of head
• Degree of caput succedaneum and moulding
During and after delivery • Time taken to apply the device (in seconds; from the start to the removal of the inserter)
• Successful application and inflation
• Any slipping of the device
• Number of contractions after application
• Integrity of the air chamber after expulsion
• Any other failure of the mechanical failure of the device
Immediate postpartum period until discharge (24–48 hours)
Maternal Incidence of:
• Episiotomy
• Lacerations of the low genital tract (vulvar, vaginal or cervical trauma)
• Perineal lacerations including cervical laceration
• Third or fourth degree perineal tear
• Uterine rupture
• Pelvic hematoma
• Perineal or vaginal hematoma
• Postpartum haemorrhage as routinely monitored at the centers
• Postpartum endometritis or infection
• Maternal blood transfusion
• Maternal pain during insertion of the device
• Maternal satisfaction
Newborn Incidence of:
• Respiratory rate at 2 hours
• Birth trauma or injuries (skull fracture, caput succedaneum, cephalohematoma,
cutaneous facial lesions and facial palsy, scalp, extracranial haemorrhages,
subgaleal haemorrhage, subaponeurotic haemorrhage, intracranial injuries)
• Low Apgar Scores (less than 7 at 1st minute and less than 7 at 5th minute)
• Admission to Neonatal Intensive Care Unit




• Evidence of infection by local standards
• Phototherapy
• Fetal or neonatal death
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Table 2 Estimated incidence rates of outcomes
Outcome incidence rate (%) Interval width 95% CI
2.0 5.8 0.4 – 6.1
4.0 7.6 1.3 – 9.0
6.0 9.0 2.6 – 11.6
8.0 10.1 4.0 – 14.1
10.0 11.1 5.4 – 16.5
12.0 11.9 7.0 – 18.9
14.0 12.6 8.5 – 21.2
16.0 13.3 10.2 – 23.5
18.0 13.9 11.8 – 25.7
20.0 14.4 13.5 – 27.9
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be performed by an obstetrician. All study participants
will have access to comprehensive emergency obstetric
and newborn care throughout the project period.
The following multi-phase plan of recruitment and
interim analysis will be put in place:
1st recruitment period (completed)
This period included 5 cases for a preliminary evaluation
of practicality, feasibility and safety. In addition to the
above-mentioned inclusion and eligibility criteria, women
had to be multiparous and to have previously experienced
a successful vaginal delivery. Results were evaluated by the
Data and Safety Monitoring Board (DSMB) that allowed
for continuation of recruitment.
Participants in the 1st phase were asked for written con-
sent to tape the application of the Odón device. These
tapes were made available to the DSMB for safety evalu-
ation purposes. Videos are kept confidentially only at the
participating centers and at the WHO coordinating unit.
2nd recruitment period (completed)
This period included an additional 25 participants (up
to the 30th participant). Participants were all multipar-
ous who had successfully delivered vaginally. Results
were evaluated by the DSMB, which allowed for con-
tinuation of recruitment.
3rd recruitment period
This period will include multiparous and nulliparous
women. The stepwise approach will be continued until
the target of 130 cases is reached. The DSMB will review
the study results after the application of the device in the
first 5–6 nulliparous women (for each site/country) and, if
no significant problems are detected, continue recruit-
ment. Afterwards, the DSMB will meet regularly after
every 15 new deliveries in order to review that information
and discuss any outcome.Data collection, data management and analysis
Case Report Forms (CRF) specifically designed in the
WHO Coordinating Unit at UNDP/UNFPA/UNICEF/
WHO/World Bank Special Programme of Research, De-
velopment and Research Training in Human Reproduction
(HRP) for this study will be used for data collection. Data
will be collected prospectively by the researchers at the
study centres and data checking and entry of the data col-
lection forms will be completed as much as possible at
the local centres. Initial data collection will be on paper
forms and then data will be entered onto a web-based
online open-source data entry system (Open Clinica)
developed and coordinated by the trial coordinating unit
at HRP. The online data entry system minimizes the de-
lays in data queries and completion of forms. These proce-
dures have been used in previous multicentre trials and
proven to be efficient and compliant with the HRP/WHO
Standard Operating Procedures and Good Clinical Prac-
tice (GCP) guidelines. Similarly, HRP has good experience
with online data entry systems from several international
multicentre studies conducted in the past five years. De-
scriptive analysis will be carried out to show the frequen-
cies of maternal and fetal complications, which will be
reported as rates or means and 95% confidence intervals.
Main problems anticipated and proposed solutions
The major anticipated problem is achieving adequate
patient recruitment. Current experience at CEMIC Uni-
versity Hospital in Buenos Aires, Argentina and the high
number of deliveries attending on an annual basis at the
proposed participating centers indicates favourable con-
ditions for study implementation and the likelihood that
patient recruitment will be successful. In addition, the
same obstetricians will assist the patient during the
prenatal, delivery, and postpartum periods. This consis-
tency in service provision will promote a close physician/
patient relationship, which will allow for a comprehensive
explanation of the objectives, benefits and risks related to
the study to women and their partners. The physician will
have enough time to familiarize women with the proce-
dures prior to the onset of labour. Participating study
sites will provide all facilities and resources for study
implementation.
Applicability of results
The expected clinical outcome of the proposed study is
that the Odón device will, when applied during the sec-
ond stage of labour, successfully and safely facilitate vagi-
nal delivery.
These results will also inform the development of future
research conducted through large pragmatic randomized
clinical trials to compare safety and effectiveness of the
Odon device with caesarean section, forceps and vacuum
extractor in cases of prolonged second stage of labour
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fetal complication.
Should this method prove to be effective and safe, it
could contribute to a reduction in maternal and newborn
complications related to childbirth, particularly in the
most vulnerable populations with the least access to
quality emergency obstetric care. The use of the device
could also contribute to efforts to counteract the in-
creasing trend in the use of caesarean sections observed
in many countries. Further studies should examine if the
device contributes to a decrease in perinatal infections
acquired through the birth canal.Ethical issues
Often new devices and procedures are introduced in med-
ical practice without having been properly evaluated in
controlled experiments with patients [19] and/or sufficient
laboratory testing [20]. One ethical pitfall of this ap-
proach is that it does not offer adequate protection to
the patients receiving the new treatment nor does it
provide sufficient evidence on safety and efficacy in order
for health care providers to evaluate appropriateness of its
use [19,20]. The present study aims at studying safety and
feasibility of a new device by means of a thoroughly
reviewed study protocol and with appropriate informed
consent procedures. These steps will ensure that the
participating women and their unborn children are not
exposed to uncontrolled testing and use of a device.
Avoiding this kind of uncontrolled experimentation is
one of the major reasons for enrolling pregnant women
in rigorous and controlled biomedical research [21].
In the context of phase 1 of the proposed study, women
enrolled in the trial will be volunteers who are experiencing
a normal pregnancy and are anticipating physiological
labour and delivery. This is not therapeutic research and
there is no significant direct benefit to the participating
women and their babies (although it is expected that the
duration of the 2nd stage of labour will be reduced,
which might result in less pain and less pushing efforts).
The benefits resulting from this study (if the device
proves efficacious) will apply to all pregnant women
worldwide. A safe, easy to apply, inexpensive device that
can be used to assist vaginal birth has the potential to
significantly impact maternal and perinatal morbidity
and even mortality. In phase 2, women with prolonged
second stage of labour might experience direct benefits.
We believe that the use of the Odón device during nor-
mal labour does not pose any additional risk to the mother
or her fetus than unassisted labour and delivery. We there-
fore consider the study risks to be minimal. However we
cannot exclude unknown risks. Determining potential risks
associated with the use of the device is one of the major
objectives of the proposed study.To ensure that potential research participants are fully
informed of the foreseeable risks and benefits of study
participation, and are aware that they are able to choose
to participate or withdraw from the study at any time,
these steps will be followed:
 Potential participants will be informed about the
study by a midwife/nurse to avoid any intimidation
that might be caused if the attending obstetrician
approached them about the study;
 Potential participants will have the opportunity to
take the information sheet home and discuss it with
the partner and family, and can make a decision
about study participation when she comes back for
the next antenatal care visit;
 Potential participants will be guaranteed easy access
to the attending obstetrician and other study
personnel in case any questions or concerns.
Data and Safety Monitoring Board (DSMB)
A DSMB will be established to ensure independent and
regular monitoring of the study, and evaluation of results
including adverse events. The role of the DSMB will be:
 to safeguard the interests of study‘s participants,
potential participants, investigators and sponsors
 to assess the safety and feasibility of the Odón
device according to data available at a predefined
schedule
 to monitor the study‘s overall conduct and quality,
and protect its validity and credibility
 to make recommendations to the study Steering
Committee concerning continuation/termination of
study or any other modification necessary based on
the observed effects of the intervention.
Detailed description of the roles and responsibilities
of the DSMC and operationalization in this study are
contained in the DSMB charter.
Ethical approvals
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